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Background: Compared with biofluids, target tissues and organs more directly reflect the pathophysiological state
of a disease process. In this study, a D-galactosamine (GalN) / lipopolysaccharide (LPS)-induced mouse model was
constructed to investigate metabonomics of liver tissue and directly characterize metabolic changes in acute liver
failure (ALF).
Methods: After pretreatment of liver tissue, gas chromatography coupled to time-of-flight mass spectrometry (GC/
TOFMS) was used to separate and identify the liver metabolites. Partial least squares – discriminant analysis models
were constructed to separate the ALF and control groups and to find those compounds whose liver levels differed
significantly between the two groups.
Results: Distinct clustering was observed between the ALF and control mice. Fifty-eight endogenous metabolites
were identified. Compared with the control mice, many metabolites, including sugars, amino acids, fatty acids, and
organic acids, underwent significant changes in the ALF group, some of which differed from changes observed in
plasma. Significant reduction of some important intermediate metabolites indicates that production of ketone
bodies, the tricarboxylic acid and urea cycles, gluconeogenesis, glycolysis and pentose phosphate pathways are
inhibited after GalN/LPS administration.
Conclusions: GC/TOFMS can be a powerful technique to perform metabonomic studies of liver tissue. GalN/LPS
treatment can severely disturb substance metabolism in the liver, with different effects on metabolites compared
with those observed in the plasma.
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Acute liver failure (ALF, sometimes referred to as fulmin-
ant hepatic failure) is a severe liver disease characterized
by encephalopathy (International Normalized Ratio ≥ 1.5)
and coagulopathy (any degree of altered mentation) in
patients with previously normal liver function. It has a
duration of less than 26 weeks and high mortality. Among
ALF patients, those whose encephalopathy occurs within
7 days of onset of jaundice are named as hyperacute liver
failure [1]. There are many causes of ALF, which vary* Correspondence: dongft_bj@sina.com; weilai@pkuph.edu.cn
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reproduction in any medium, provided the orin different countries. Currently, ALF related to drugs
(including acetaminophen) accounts for more than 50% of
all cases in some western societies, and hepatitis B virus
(HBV) is still a relevant trigger, which is responsible for
approximately 7% of cases in the US and 10% in Germany
[2,3]. In contrast, viral hepatitis, especially hepatitis B, is
the most important cause in China. However, following
the application of antiviral drugs including various nucleo-
side analogues, hepatitis B-related ALF has decreased and
drug-induced ALF has gradually increased in China.
The liver, as a center of substance and energy metab-
olism, undertakes principal synthesis, decomposition,
excretion, transformation and other metabolic pro-
cesses. Moreover, some of the enzymes and functions
are liver-specific. These metabolic processes are likelyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of liver dysfunction, the variation may be different.
ALF almost certainly results in significant changes of
liver metabolites because of its rapid and severe liver
cell necrosis; however, metabolic profiling of changes
induced by ALF have not been well characterized. As
an important analytical technology, metabonomics has
been increasingly applied to various liver diseases, such as
nonalcoholic fatty liver disease [4], liver cirrhosis [5], and
hepatocellular carcinoma [6,7]. In previous studies, we
performed plasma metabonomic analysis in BALB/c mice
with fulminant hepatic failure induced by treatment with
D-galactosamine (GalN) / lipopolysaccharide (LPS) [8,9].
Among 45 metabolites identified, some showed significant
differences in plasma in response to GalN/LPS. However,
assessment of liver tissue metabolites is of great value in
metabonomic studies because it can provide more direct
information on metabolism compared with assessment of
biofluids.
In the current study, we performed metabonomic ana-
lysis of liver tissue in the GalN/LPS mouse model with




Male BALB/c mice (n = 24, 18–22 g) were purchased
from the Academy of Military Medical Sciences (Beijing,
China) and housed in a standard animal laboratory with
a 12 h light–dark cycle. They were provided with water
and standard mouse chow ad libitum and randomly di-
vided into GalN/LPS-induced ALF (n = 10) and control
(n = 10) groups. The current studies were carried out in
accordance with the Chinese National Research Council
guidelines and approved by the Subcommittee on Research
Animal Care and Laboratory Animal Resources of the
Peking University People’s Hospital.
Establishment of ALF model and collection of liver tissue
The ALF model was established as described previously,
with slight modification [8]. Approximately 6 h after
GalN/LPS or saline treatment, the mice were sacrificed
and the liver was immediately perfused through the left
ventricle with chilled saline containing 25 U/mL heparin.
Liver tissue was harvested in tubes and immediately
snap-frozen in liquid nitrogen. After 2 h, the liver samples
were transferred to −80°C and stored at this temperature
until analysis. Serum biochemistry and liver histopath-
ology were used to assess liver injury as previously
reported [8].
Pretreatment of liver tissue
A screw-cap vial was filled at least half full with 0.5 mm
zirconia-silica beads. Liver tissue (200 mg) and extractionsolvents (a mixture of chloroform, acetonitrile and water
(1:2:1, v/v/v) were then added, ensuring that the microtube
was filled almost to the top. Liver samples were homog-
enized using aMini-BeadBeater-16 (Biospec Co., USA)
for 5 min and the vials cooled in ice-water for 1 min,
then 20 μL of a ribitol stock solution (0.2 mg/mL in
H2O) was added as an internal standard. The mixture was
placed on a shaker at 70°C for 15 min and centrifuged at
10,000 × g for 10 min. The supernatant was separated,
transferred into a GC vial, and then evaporated to dryness
under a stream of N2 gas.
Metabolites in liver samples were derivatized prior to gas
chromatography coupled to time-of-flight mass spectrom-
etry (GC/TOFMS) analysis. Methoxyamine hydrochloride
(20 μL, 20 mg/mL pyridine) was added to the dried fraction
above, and continuously shaken at 30°C for 90 min.40 μL
of N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA)
with 1% TMCS was added and incubated at 37°C for
30 min. It was then kept at room temperature for 120 min
before injection.
All chemicals were purchased from Sigma-Aldrich
Chemical Co., Steinheim, Germany.GC-TOFMS analysis
The GC/TOFMS system consisted of an HP 6890 gas
chromatograph and a time-of-flight mass spectrometer
(Waters Co., Milford, MA, USA). Derivatized solutions
(0.3 μL) were injected into a 30 m DB-5 column (250 μm
i.d., 0.25 μm film; Agilent Technologies, Palo Alto, CA,
USA) with 1 mL/min of helium as the carrier gas at a
split ratio of 25:1. The temperatures of the injection,
interface, and ion source were set at230°C, 290°C and
220°C, respectively. To achieve optimal separation, a
gradient temperature program was set. After a 5-min
solvent delay time at 70°C, the oven temperature was
increased to 310°C in increments of 5°C/min, followed
by a 1 min isocratic cool down to 70°C and an add-
itional 5-min delay. MassLynx software (Waters Co.)
was used to acquire the chromatographs. To identify
the metabolites, NIST02 libraries with electron impact
(EI) spectra were searched rigorously for all the peaks
detected with the total ion current (TIC). Compounds
were also identified by comparison of their mass spectra
and retention times with those of commercially avail-
able references.Data processing and pattern recognition
Each sample was represented by a GC/TOFMS TIC
chromatograph. Ribitol was added as an internal standard
to correct minor variations during sample preparation and
analysis. The relative intensity of each metabolite was nor-
malized and expressed as 100 times the ratio of its peak
area to that of ribitol on the same chromatograph.
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MarkerLynx applications manager software (Waters Co.),
which incorporates a peak deconvolution package that al-
lows the detection and retention-time alignment of the
peaks eluting in each data file. MarkerLynx extracts com-
ponents using mass chromatograms and lists the detected
peaks according to their masses and retention times, to-
gether with their associated intensities. All the output data
were exported from MarkerLynx to SIMCA-P plus
(Umetrics, Sweden) for partial least squares discriminant
analysis (PLS-DA) combined with orthogonal signal cor-
rection (OSC) to construct mathematical boundaries
around each class and thereby maximize the separation
between classes.
Statistical analysis
Values are presented as mean ± SD. Comparisons of the
measured metabolite intensities of the control and ALF
groups were made using the unpaired Student’s t test with
two-tailed distribution. P-values < 0.05 were considered
statistically significant.
Results
Manifestations of the GalN/LPS-treated mouse model
Preliminary experiments showed that 80-90% of the
mice were dead by approximately 6.5 h after GalN/LPS
treatment because of the development of ALF. Com-
pared with mice in the control group, GalN/LPS-treated
mice showed slow movement and reactions, scattered
hair, and very tumescent livers 6 h after treatment. With
respect to liver morphology, GalN/LPS-treated mice
presented with severe liver congestion, inflammation
and massive necrosis as previously reported [8].
GC/TOFMS TIC chromatogram of liver tissues
The GC/TOFMS TIC chromatograms of liver samples
from the saline control and GalN/LPS treatment groups
are shown in Figure 1. The horizontal axis represents
the time at which metabolites occur, and the vertical axis
abundance. Each peak corresponds to a compound, and
the figures above them represent their retention times.
The area under a peak represents the relative abundance
of the metabolite. Significant differences between the
TIC profiles of the control and treatment groups were
observed (Figure 1).
Differences in scores plots between the control and ALF
groups
To explore metabolic differences of liver tissues between
the ALF model and the control group, the GC/TOFMS
data were analyzed using multivariate statistics. The PLS-
DA model (R2Y = 0.996, Q2Y = 0.72) shows clear separation
between model and control samples (Figure 2). The firstand second components accounted for 18.2% and 15.5% of
the variance, respectively.
Identification of endogenous metabolites in liver tissue
Two hundred and forty-three peaks were detected from
GC/TOFMS TIC chromatographs of liver tissue. Based
on the comparison with NIST02 libraries and commer-
cially available reference compounds, 58 of the peaks were
confirmed to be endogenous metabolites, such as sugars,
amino acids, fatty acids, and organic acids. For further
analysis, the metabolites were divided into an amino acid
group and a non-amino acid group (Tables 1 and 2).
Changes of metabolite levels after GalN/LPS treatment
The GC/TOFMS chromatograms showed changes in
liver amino acid levels after GalN/LPS treatment. Fifteen
amino acids were identified. Compared with the control
group, levels of five amino acids (glycine, B-alanine, pro-
line, glutamate and tyrosine) decreased and only lysine in-
creased significantly in the ALF group. Levels of the other
amino acids, as well as levels of total and gluconeogenic
amino acids, were not different between the two groups
(Table 1).
Forty-three non-amino acid metabolites were identi-
fied. Compared with those of the control group, levels
of 22 metabolites decreased, 20 metabolites remained
unchanged, and only one metabolite increased in liver
tissues of mice from the ALF group. Among the eight
sugars identified, fructose, glucose, mannose, 6-deoxy-
mannose and sedoheptulose decreased, and only mal-
tose was elevated. Lipids identified included saturated
and unsaturated fatty acids, and some lipoids. Among
saturated fatty acids, the level of tetradecanoic acid
decreased, while palmitic acid and stearic acid showed
no difference due to treatment. Among unsaturated
fatty acids, the level of arachidonic acid decreased, while
the remainder, including linoleic acid, oleic acid and
docosahexaenoic acid, showed no differences between the
two groups. Among lipoids, levels of phosphoglyceride,
glucopyranose phosphate, fructose phosphate and choles-
terol decreased significantly in the ALF group. Among
other metabolites, β-hydroxybutyrate, urea, phosphate,
succinic acid, erythronic acid, 2,3,4-trihydroxy-butanal,
hypoxanthine, arabinonic acid, gluconic acid, purine,
inositol monophosphate and adenosine also decreased
significantly in the ALF group.
Discussion
As one analytical technology for systems biology,
metabonomics has displayed great power in screening
metabolic biomarkers, describing metabolic pathways,
and interpreting the function of complex biological sys-
tems [10]. Both biofluids and tissues can be used as sam-
ples for metabonomic analysis. Biofluids are used more
Figure 1 Comparison of GC/TOFMS total ion current (TIC) chromatographs of liver tissue from mice in the control (A) and ALF (B)
groups. Each peak represents a metabolite, and the figures above the peaks represent their retention times.
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in a relatively non-invasive manner. However, the majority
of substances in biofluids are easily affected. For example,
because blood is a transport organ, exogenous materials
are transported to various organs, and endogenous sub-
stances are exchanged between different organs by plasma.
Lesions of each organ may change levels of plasma metab-
olites and thus affect plasma metabonomics. Therefore, in
the case of a disease, the target tissue or organ may be
more important than biofluids for metabonomic analysis
because it can directly reflect pathophysiological responses
to the disease process [11].
Based on the GC/TOFMS chromatograms, it was ob-
served that GalN/LPS treatment induced significant
changes of some metabolite levels in the liver. In total,
compared with those of the control group, levels of 27metabolites decreased, 29 metabolites did not change,
and only two metabolites increased in liver tissues of
mice in the ALF group.
Among the amino acids identified, liver levels of
glycine, B-alanine, proline, glutamate and tyrosine de-
creased and lysine increased significantly in the ALF
group. There were no differences in the total levels of
amino acids between the two groups. In the case of
sugars, the levels of fructose, glucose, mannose, 6-
deoxy-mannose and sedoheptulose all decreased while
maltose was elevated. Among fatty acids, tetradecanoic
acid and arachidonic acid decreased. Most lipoids in-
cluding phosphoglyceride, glucopyranose phosphate,
fructose phosphate and cholesterol decreased signifi-
cantly in the ALF group. Many other metabolites, such
as β-hydroxybutyrate, urea, phosphate, and succinic
Figure 2 Scores plot for PLS-DA of GC/TOFMS data derived from liver tissue of control and ALF mice. The scores plot shows distinct
clustering of the control and ALF groups. Triangle and diamond shapes represent control and ALF model groups, respectively.
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ALF group.
Changes in the liver levels of many metabolites were
inconsistent with their levels in plasma. In our previous
study, significantly elevated levels of almost all of the
identified amino acids were observed in GalN/LPS-treated
mice compared with those in the control group. In con-
trast, in the current study several metabolites (including
phosphate, phosphoglyceride, fumaric acid and malic acid)
that previously showed elevated plasma levels either de-
creased, or did not change, in liver tissue. Furthermore,Table 1 Comparison of liver amino acid levels between the co


















a Total amino acids. bGluconeogenic amino acids include aspartate, serine, glycine,
of metabolite levels between ALF and control groups.urea and glucose, which showed no change in plasma, de-
creased in the liver tissue of the ALF group. It is well
known that plasma metabonomics reflects systemic meta-
bolic effects associated with GalN/LPS stimuli, while
tissue-targeted metabonomic analyses enable more precise
investigation of local metabolism. ALF is a severe liver dis-
order with devastating consequences and it encompasses a
pathophysiological response associated with rapid deteri-
oration of liver functions. Its pathology presents as severe
hepatocyte inflammation, massive apoptosis and/or necro-
sis [12]. A multitude of metabolites inside liver cells arentrol and ALF groups
Control Group ALF Group Ratioc P
197.63 ± 25.91 162.54 ± 23.76 0.82 0.0889
81.52 ± 9.32 79.34 ± 13.53 0.97 0.8230
41.67 ± 8.16 43.00 ± 5.56 1.03 0.8026
44.91 ± 11.28 50.17 ± 6.79 1.12 0.5499
157.18 ± 18.62 120.83 ± 11.80 0.77 0.0208
98.42 ± 7.32 100.49 ± 9.06 1.02 0.7926
88.84 ± 10.42 77.97 ± 7.22 0.88 0.1624
38.87 ± 9.79 19.36 ± 1.63 0.50 0.0182
99.95 ± 17.81 74.37 ± 7.51 0.74 0.0472
54.20 ± 11.68 50.40 ± 4.85 0.93 0.6024
98.41 ± 15.86 77.18 ± 5.01 0.78 0.0491
2.06 ± 0.81 2.60 ± 0.78 1.26 0.5246
41.78 ± 10.86 67.31 ± 14.79 1.61 0.1087
67.81 ± 9.84 32.34 ± 9.02 0.48 0.0008
10.61 ± 1.61 64.29 ± 12.27 6.06 0.0008
1123.87 ± 115.19 1022.21 ± 113.20 0.91 0.2207
1003.66 ± 118.93 858.26 ± 85.36 0.86 0.0656
threonine, alanine, proline, lysine, tyrosine, valine, and isoleucine. cMeans ratio
Table 2 Comparison of non-amino acid metabolite levels between the control and ALF groups
No. Retention Time Metabolites Control Group ALF Group Ratioa P
16 6.02 lactate 238.84 ± 36.26 233.85 ± 38.91 0.98 0.8318
17 7.88 ethanedioic acid 5.92 ± 2.28 4.06 ± 1.51 0.69 0.1749
18 8.39 β-hydroxybutyrate 17.43 ± 1.96 5.09 ± 1.95 0.29 0.0017
19 10.91 urea 43.17 ± 6.07 20.54 ± 2.04 0.48 0.0013
20 11.20 phosphate 61.90 ± 10.34 38.67 ± 8.61 0.62 0.0279
21 11.30 glycerol 502.25 ± 42.61 459.58 ± 41.69 0.92 0.1886
22 12.35 succinic acid 30.58 ± 2.72 3.76 ± 1.68 0.12 0.0000
23 12.90 uracil 26.65 ± 5.82 29.78 ± 8.73 1.12 0.6393
24 13.31 fumaric acid 12.96 ± 3.60 11.67 ± 4.08 0.90 0.6120
25 13.78 pyruvate acid 8.46 ± 1.62 8.75 ± 0.96 1.03 0.7939
26 16.76 malic acid 45.24 ± 8.33 48.72 ± 4.17 1.08 0.4257
27 17.70 4-amino-butanoic acid 29.14 ± 3.50 33.28 ± 9.01 1.14 0.4762
28 18.50 erythronic acid 3.06 ± 0.77 1.01 ± 0.32 0.33 0.0064
29 19.28 2-piperidinedicarboxylic acid 19.73 ± 6.01 13.73 ± 5.56 0.70 0.0985
30 21.20 2,3,4-trihydroxy-butanal 99.30 ± 10.48 52.41 ± 12.11 0.53 0.0021
31 23.07 phosphoglyceride 114.73 ± 29.17 31.67 ± 9.72 0.28 0.0014
32 23.43 2-(bisamino)ethyl-phosphoric acid 48.32 ± 7.80 44.76 ± 9.20 0.93 0.3720
33 23.86 hypoxanthine 96.71 ± 15.64 62.57 ± 7.83 0.65 0.0425
34 24.26 arabinonic acid 1.66 ± 0.59 36.94 ± 5.53 22.25 0.0003
35 24.90 tetradecoic acid 74.92 ± 7.62 49.23 ± 8.42 0.66 0.0058
36 25.33 fructose 5.97 ± 1.30 3.19 ± 0.85 0.53 0.0092
37 25.63 glucose 439.00 ± 67.12 360.72 ± 42.74 0.82 0.0450
38 25.72 mannose 64.66 ± 14.56 37.53 ± 12.48 0.58 0.0137
39 26.22 galactose 158.06 ± 41.44 123.44 ± 19.37 0.78 0.0703
40 27.13 gluconic acid 66.74 ± 12.23 11.59 ± 4.73 0.17 0.0002
41 27.55 glucopyranose 98.84 ± 37.07 73.62 ± 27.60 0.74 0.3248
42 27.69 pantothenic acid 2.61 ± 1.12 2.47 ± 1.36 0.95 0.8489
43 28.18 purine 72.29 ± 18.01 35.07 ± 5.22 0.49 0.0180
44 28.48 6-deoxy-mannose 28.08 ± 7.66 10.19 ± 2.39 0.36 0.0052
45 28.84 palmitic acid 154.73 ± 16.61 162.99 ± 6.64 1.05 0.4927
46 29.54 inositol 85.87 ± 1.51 83.94 ± 6.01 0.98 0.5510
47 30.44 sedoheptulose 20.10 ± 7.80 3.07 ± 1.40 0.15 0.0121
48 31.82 linoleic acid 155.45 ± 17.62 144.69 ± 10.84 0.93 0.3358
49 31.93 oleic acid 116.51 ± 15.37 105.46 ± 7.70 0.91 0.3304
50 32.40 stearic acid 79.60 ± 5.93 83.70 ± 2.35 1.05 0.2288
51 33.63 glucopyranose phosphate 4.34 ± 1.76 2.36 ± 0.77 0.54 0.0538
52 32.44 arachidonic acid 62.30 ± 9.64 41.11 ± 8.21 0.66 0.0103
53 35.07 inositol monophosphate 5.50 ± 0.76 2.66 ± 0.70 0.48 0.0030
54 37.31 fructose phosphate 13.23 ± 4.61 0.50 ± 0.20 0.04 0.0061
55 37.44 ducosahexenoic acid 37.45 ± 5.03 37.42 ± 14.06 1.00 0.9963
56 37.70 adenosine 197.33 ± 36.90 29.66 ± 9.87 0.15 0.0008
57 40.15 maltose 41.62 ± 11.28 80.62 ± 27.90 1.94 0.0390
58 45.60 cholesterol 66.99 ± 11.90 35.54 ± 8.76 0.53 0.0330
aMeans ratio of metabolite levels between ALF and control groups.
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liver levels of metabolites.
Massive apoptosis and/or necrosis cause deterior-
ation of liver function. At the same time, the majority
of amino acids, sugars, and fatty acids (among other
metabolites) decrease significantly in liver tissues in
ALF. The consequent lower levels of many metabolites
inside liver cells thus fail to provide sufficient raw ma-
terials for further biosynthesis and energy metabolism.
An absolute reduction of β-hydroxybutyrate, succinic
acid and urea, and a relative reduction of fumaric acid
and malic acid, indicate that the production of ketone
bodies, tricarboxylic acid and urea cycles are signifi-
cantly inhibited during ALF.A significant decrease of
fructose phosphate illustrates that the gluconeogenesis,
glycolysis and pentose phosphate pathways may also be
disturbed. The significant decrease of liver levels of
hypoxanthine, purine and adenosine suggest that ex-
posure to GalN/LPS disrupts nucleotide metabolism.
These disturbed pathways are related to several mecha-
nisms of GalN/LPS injury to the liver. Oxidative stress
is induced by release and accumulation of many react-
ive oxygen species in response to GalN/LPS. Reactive
oxygen species are fatal to liver cells and result in cell
death [13]. Significantly decreased levels of the polyun-
saturated fatty acid arachidonic acid show evidence of
lipid peroxidation [14]. Finally, GalN depletes the uri-
dine triphosphate pool and thus inhibits mRNA and
protein synthesis [15].Conclusions
GC/TOFMS combined with multivariable statistics can be
used to perform metabonomics analysis of liver samples.
Compared with control mice, significant differences in the
liver levels of many metabolites were found in the ALF
mouse model, and some of these changes in liver differed
from those observed in plasma. Distinct clustering was
observed between the ALF and control mice. Significant
reductions of some important intermediate metabolites in-
dicate that production of ketone bodies, the tricarboxylic
acid and urea cycles, gluconeogenesis, glycolysis and pen-
tose phosphate pathways are inhibited after GalN/LPS
administration. Liver-targeted metabonomic analyses are
able to provide relatively direct and precise information
regarding localized changes in metabolism in ALF.
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